Clinicopathological characteristics, treatment, and survival outcomes of cystadenocarcinoma of the salivary gland: a population-based study
Authors Cai CF, Sun JY, He Z, Lin HX, Liu FR, Wang Y
Received 23 April 2016
Accepted for publication 1 September 2016
Published 25 October 2016 Volume 2016:9 Pages 6569—6572
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 2
Editor who approved publication: Dr Jianmin Xu
Cheng-Fu Cai,1,2,* Jia-Yuan Sun,3,* Zhen-Yu He,3 Huan-Xin Lin,3 Fa-Rong Liu,2,4 Yan Wang3
1Department of Otolaryngology-Head and Neck Surgery, Affiliated First Hospital, Medical College, Xiamen University, 2Teaching Hospital of Fujian Medical University, Xiamen, 3Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 4Department of Psychology, Affiliated First Hospital, Medical College, Xiamen University, People’s Republic of China
*These authors contributed equally to this work
Background: The aim of this study was to investigate the clinicopathological characteristics, treatment, and survival of cystadenocarcinoma of the salivary gland.
Patients and methods: Cases in the Surveillance, Epidemiology, and End Results database from 1991 to 2012 were identified. Factors significantly associated with survival were identified using Kaplan–Meier survival analysis and Cox proportional hazard regression.
Results: A total of 65 patients were identified; of these patients, 64 received surgical treatment, 25 underwent lymphadenectomy, and four (16.0%) patients had nodal metastasis and only one (2.1%) patient had poorly differentiated disease. The most common tumor location was the parotid gland (87.7%). The median follow-up was 55 months. None of the patients died of salivary gland malignant-tumor-related disease. The 5- and 10-year cause-specific survival rates were 97.0% and 81.4%, respectively. The 5- and 10-year overall survival rates were 84.6% and 60.7%, respectively. Surgical procedures, lymphadenectomy, and adjuvant radiotherapy did not affect survival.
Conclusion: Salivary gland cystadenocarcinoma is extremely rare but has an excellent prognosis, and surgery is the mainstay of treatment.
Keywords: cystadenocarcinoma, salivary gland, SEER, treatment, survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]